Pepinemab Shows Promise Reshaping Tumor Immunity in Melanoma Trial
New clinical data from Vaccinex suggests its SEMA4D-blocking drug pepinemab may help coordinate immune responses against melanoma tumors.
A newly published study from a neoadjuvant melanoma clinical trial offers fresh evidence that blocking a protein called SEMA4D can alter the immune landscape within tumors, potentially enabling the body's own defenses to mount a more organized attack on cancer cells, according to data from Vaccinex.
The findings center on pepinemab, Vaccinex's investigational antibody designed to inhibit SEMA4D, a signaling molecule that researchers believe plays a role in suppressing immune activity near tumors. By neutralizing that signal in the neoadjuvant setting — meaning treatment was administered before surgery — investigators observed changes in the tumor immune environment that the company characterizes as consistent with a coordinated immune response.
Read more OrbitronAI and Aramco Digital Form Industrial AI Partnership at LEAP 2026 →
Neoadjuvant trials are considered particularly informative because researchers can compare tumor tissue collected before and after treatment, giving them a direct window into how a drug is reshaping the biology of a cancer. The melanoma study follows that model, and Vaccinex says the published results add meaningful clinical support to a mechanism previously demonstrated primarily in preclinical work.
Melanoma remains one of the most immunologically active solid tumors, making it a logical testing ground for immune-modulating therapies. The neoadjuvant context also offers a practical advantage: response data can emerge faster than in adjuvant or metastatic settings, potentially accelerating development timelines for drugs like pepinemab.
The publication represents a scientific milestone for Vaccinex as it works to build a clinical and mechanistic case for SEMA4D blockade across oncology indications. Continue reading at GlobeNewswire - Industry News on Financial Services.
